S100A12 and RAGE Expression in Human Bladder Transitional Cell Carcinoma: a Role for the Ligand/RAGE Axis in Tumor Progression?

  • Khorramdelazad, Hossein (Molecular Medicine Research Center, Rafsanjan University of Medical Sciences) ;
  • Bagheri, Vahid (Molecular Medicine Research Center, Rafsanjan University of Medical Sciences) ;
  • Hassanshahi, Gholamhossein (Molecular Medicine Research Center, Rafsanjan University of Medical Sciences) ;
  • Karami, Hormoz (Department of Urology, Shahid Rahnemoon Hospital, Shahid Sadoughi University of Medical Sciences and Health Services) ;
  • Moogooei, Mozhgan (Molecular Medicine Research Center, Rafsanjan University of Medical Sciences) ;
  • Zeinali, Masoud (Department of Social Medicine, Faculty of Medicine, Rafsanjan University of Medical Sciences) ;
  • Abedinzadeh, Mehdi (Department of Urology, Shahid Rahnemoon Hospital, Shahid Sadoughi University of Medical Sciences and Health Services)
  • Published : 2015.04.14


Background: Transitional cell carcinoma (TCC) and prostate cancer are the most frequent cancers in the male genitourinary tract. Measurement of biological biomarkers may facilitate clinical monitoring and aid early diagnosis of TCC. The aim of the present investigation was to detect the mRNA levels of S100A12 and RAGE (receptor for advanced glycation end products) in patients suffering from bladder TCC. Materials and Methods: To explore the involvement of S100A12 and RAGE genes, total RNA was harvested from cancer tissues and samples obtained from normal non-tumorized urothelium of the same patients. Quantitative PCR (qPCR) was subsequently employed to determine the mRNA levels of S100A12 and RAGE. Results: The results showed that mRNA expression of S100A12 and RAGE was significantly up-regulated in the cancer tissue. Conclusions: According to the results presented in the current study, mRNA expression of S100A12 and RAGE might be as a useful biomarker for TCC. Therefore, this ligand-receptor axis possibly plays important roles in the development of TCC and may serve either as an early diagnostic marker or as a key factor in monitoring of response to treatment. More research is required concerning inhibition of the S100A12-RAGE axis in different cancer models.


TCC;bladder cancer;S100A12;RAGE


Supported by : Rafsanjan University of Medical Sciences


  1. Arumugam T, Ramachandran V, Gomez SB, Schmidt AM, Logsdon CD (2012). S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res, 18, 4356-64.
  2. Chen H, Xu C, Jin Q, Liu Z (2014). S100 protein family in human cancer. Am J Cancer Res, 4, 89-115.
  3. DiNorcia J, Lee MK, Moroziewicz DN, et al (2012). RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg, 16, 104-12.
  4. Donato R (2003). Intracellular and extracellular roles of S100 proteins. Microsc Res Tech, 60, 540-51.
  5. Donato R, Cannon B, Sorci G, et al (2013). Functions of S100 proteins. Curr Mol Med, 13, 24-57.
  6. Elangovan I, Thirugnanam S, Chen A, et al (2012). Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun, 417, 1133-8.
  7. Fritz G (2011). RAGE: a single receptor fits multiple ligands. Trends Biochem Sci, 36, 625-32.
  8. Funk S, Mark R, Bayo P, et al (2014). High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma. Int J Cancer, [Epub ahead of print].
  9. Gui Y, Guo G, Huang Y, et al (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet, 43, 875-8.
  10. Gupta S, Hussain T, MacLennan GT, et al (2003). Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol, 21, 106-12.
  11. Heilmann RM, Wright ZM, Lanerie DJ, Suchodolski JS, Steiner JM (2014). Measurement of urinary canine S100A8/A9 and S100A12 concentrations as candidate biomarkers of lower urinary tract neoplasia in dogs. J Vet Diag Invest, 26, 104-12.
  12. Kataoka K, Ono T, Murata H, et al (2012). S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett, 3, 1149-53.
  13. Knowles MA, Hurst CD (2015). Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer, 15, 25-41.
  14. Lee S-J, Lee E-J, Kim S-K, et al (2012). Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS ONE, 7, 40267.
  15. Luo A, Kong J, Hu G, et al (2004). Discovery of $Ca2{\pm}relevant$ and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene, 23, 1291-9.
  16. Matsumoto K, Irie A, Satoh T, et al (2007). Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology, 70, 602-7.
  17. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ (2011). The role of S100 genes in breast cancer progression. Tumor Biol, 32, 441-50.
  18. Meijer B, Gearry R, Day A (2012). The role of S100A12 as a systemic marker of inflammation. Int J Inflam, 2012, 907078.
  19. Memon AA, Sorensen BS, Meldgaard P, et al (2005). Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res, 11, 606-11.
  20. Nagy N, Brenner C, Markadieu N, et al (2001). S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest, 81, 599-612.
  21. Pietzsch J (2011). S100 proteins in health and disease. Amino Acids, 41, 755-60.
  22. Ranasinghe WK, De Silva D, De Silva M, et al (2012). Incidence of bladder cancer in sri lanka: analysis of the cancer registry data and review of the incidence of bladder cancer in the South asian population. Korean J Urol, 53, 304-9.
  23. Salama I, Malone PS, Mihaimeed F, Jones JL (2008). A review of the S100 proteins in cancer. Eur J Surg Oncol, 34, 357-64.
  24. Salehi A, Khezri A, Malekmakan L, Aminsharifi A (2011). Epidemiologic status of bladder cancer in Shiraz, southern Iran. Asian Pac J Cancer Prev, 12, 1323-7.
  25. Sessa L, Gatti E, Zeni F, et al (2014). The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS ONE, 9, 86903.
  26. Shakhssalim N, Hosseini SY, Basiri A, et al (2010). Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev, 11, 601-6.
  27. Xie J, Mendez JD, Mendez-Valenzuela V, Aguilar-Hernandez MM (2013). Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal, 25, 2185-97.
  28. Yao R, Davidson D, Lopez Beltran A, et al (2007a). The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol, 22, 1025-32.
  29. Yao R, Lopez-Beltran A, Maclennan GT, et al (2007b). Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res, 27, 3051-8.
  30. Yaser AM, Huang Y, Zhou RR, et al (2012). The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci, 13, 5982-97.
  31. Yin C, Li H, Zhang B, et al (2013). RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat, 142, 297-309.
  32. Zhang G, Li M, Jin J, Bai Y, Yang C (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.
  33. Zhao CB, Bao JM, Lu YJ, et al (2014). Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res, 4, 369-77.
  34. Zhao FT, Jia ZS, Yang Q, Song L, Jiang XJ (2013). S100A14 promotes the growth and metastasis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 3831-6.

Cited by

  1. Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or urogenital tract carcinoma vol.13, pp.1, 2017,